docetaxel + liposomal doxorubicin + metformin + trastuzumab

This is a combination regimen consisting of four agents: docetaxel, liposomal doxorubicin, metformin, and trastuzumab. **Docetaxel** is a taxane-class chemotherapeutic that inhibits microtubule depolymerization, thereby blocking cell division[4]. **Liposomal doxorubicin** (including pegylated forms such as Doxil or Myocet) is an anthracycline antibiotic encapsulated in liposomes to reduce cardiotoxicity and improve tumor targeting; it intercalates DNA and inhibits topoisomerase II[2][5]. **Metformin** is a biguanide antidiabetic agent that reduces hepatic glucose production and increases insulin sensitivity; it has also been investigated for potential anticancer effects via AMPK activation. **Trastuzumab** is a monoclonal antibody targeting the HER2/neu receptor, inhibiting proliferation of HER2-overexpressing tumor cells[2]. This combination targets multiple pathways involved in cancer cell growth and survival. The use of pegylated or nonpegylated liposomal formulations of doxorubicin aims to minimize cardiac toxicity compared to conventional anthracyclines when combined with trastuzumab[2][5]. Clinical studies have evaluated similar combinations (without metformin) for HER2-positive breast cancer in neoadjuvant settings with promising efficacy and manageable safety profiles[2].

Other names

PLD (pegylated liposomal doxorubicin)LD (liposomal doxorubicin)